USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington

Jubilant HollisterStier is a subsidiary of Jubilant Pharma Holding

FDA issues warning letter to Philips over manufacturing and quality system deficiencies

The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days

BMS unveils new data highlighting sustained efficacy and safety of Sotyktu in psoriatic arthritis and lupus

Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions

Jubilant HollisterStier launches new sterile fill & finish line at its Spokane facility in US

The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision

Lilly to build $5 billion manufacturing facility in Virginia

This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year

Tonix receives FDA approval of Tonmya for treatment of fibromyalgia

Surendralal Karsanbhai elected to Merck Board of Directors

With the addition of Karsanbhai, the Merck board will consist of 13 members

YS Biopharma appoints new Directors

The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024

Amgen settles with FTC over US$28 billion deal

Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products

Jemperli plus chemotherapy approved in the US as the first new frontline treatment option for dMMR/MSI-H primary advanced or recurrent endometrial cancer

Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy